TY - JOUR
T1 - Immunosuppression in melanoma immunotherapy
T2 - Potential opportunities for intervention
AU - Lizée, Gregory
AU - Radvanyi, Laszlo G.
AU - Overwijk, Willem W.
AU - Hwu, Patrick
PY - 2006/4/1
Y1 - 2006/4/1
N2 - Although melanomas are substantially more immunogenic than other tumors, current immunotherapeutic approaches for melanoma patients have met with only limited success. Although melanoma-specific CD8+ T-cell responses can often be generated in patients naturally or through vaccination regimens, tumors frequently continue to grow unabated, suggesting that tumor-specific immune responses may be actively dampened in vivo. Research over the past decade has brought to light several mechanisms used by melanomas and other tumors to suppress tumor-specific immune responses. These include the presence of regulatory immune cells within the tumor microenvironment and draining lymph nodes that serve to shut down effector T-cell function. In addition, melanoma tumors themselves express a number of soluble and membrane-bound molecules that are responsible for inhibiting activated immune cells. The identification of these suppressive mechanisms has provided significant opportunities for designing novel therapeutic interventions that could augment current vaccination and adoptive transfer approaches for treatment of melanoma.
AB - Although melanomas are substantially more immunogenic than other tumors, current immunotherapeutic approaches for melanoma patients have met with only limited success. Although melanoma-specific CD8+ T-cell responses can often be generated in patients naturally or through vaccination regimens, tumors frequently continue to grow unabated, suggesting that tumor-specific immune responses may be actively dampened in vivo. Research over the past decade has brought to light several mechanisms used by melanomas and other tumors to suppress tumor-specific immune responses. These include the presence of regulatory immune cells within the tumor microenvironment and draining lymph nodes that serve to shut down effector T-cell function. In addition, melanoma tumors themselves express a number of soluble and membrane-bound molecules that are responsible for inhibiting activated immune cells. The identification of these suppressive mechanisms has provided significant opportunities for designing novel therapeutic interventions that could augment current vaccination and adoptive transfer approaches for treatment of melanoma.
UR - http://www.scopus.com/inward/record.url?scp=33646268668&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33646268668&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-05-2537
DO - 10.1158/1078-0432.CCR-05-2537
M3 - Review article
C2 - 16609059
AN - SCOPUS:33646268668
SN - 1078-0432
VL - 12
SP - 2359s-2365s
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 7 II
ER -